secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACELYRIN, Inc. (—)
CIK:        0001962918
Form:       8-K/A
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001962918-24-000117
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

ACELYRIN estimates ~$11.5M restructuring charges; cuts 40 jobs, halts izokibep in HS/PsA/AxSpa
--------------------------------------------------------------------------------

- Workforce reduced by 40 employees (~1/3 headcount); one-time severance costs estimated at $4.3M.
- Suspension of izokibep development in HS, PsA, AxSpa; focus shifts to lonigutamab for thyroid eye disease.
- Cancellation of manufacturing services yields net charge of ~$7.2M ($42.9M cash expense netted with $35.7M credit voucher).
- Q3 2024 restructuring charges preliminarily estimated at $3.6M severance plus full $7.2M manufacturing cancellation charge.
- Credit voucher expected to offset future manufacturing costs for lonigutamab through Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/0001962918-24-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962918/000196291824000117/slrn-20240810.htm
  HTML page:      https://secwatch.observer/filing/0001962918-24-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer